| Symbol | LEXX |
|---|---|
| Name | LEXARIA BIOSCIENCE CORP. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 100-740 MCCURDY ROAD, KELOWNA, British Columbia, V1X 2P7, Canada |
| Telephone | +1 250 765-6424 |
| Fax | — |
| — | |
| Website | https://www.lexariabioscience.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001348362 |
| Description | Lexaria Bioscience Corps patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio. Additional info from NASDAQ: |
Director BUNKA CHRISTOPHER 🔴 sold 284.8K shares (7 derivative) of Lexaria Bioscience Corp. (LEXX) at $3.00 Transaction Date: Mar 17, 2026 | Filing ID: 000001
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNew Form 25-NSE - Lexaria Bioscience Corp. Filed: 2026-01-14 AccNo: 0001354457-26-000039 Size: 3 KB
Read moreNew Form S-3 - Lexaria Bioscience Corp. Filed: 2025-12-29 AccNo: 0001640334-25-002382 Size: 477 KB
Read moreNew Form 424B5 - Lexaria Bioscience Corp. Filed: 2025-12-16 AccNo: 0001640334-25-002331 Size: 349 KB
Read moreNew Form DEF 14A - Lexaria Bioscience Corp. Filed: 2025-12-10 AccNo: 0001640334-25-002275 Size: 1 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06648031 | Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and… | Phase1 | Type2diabetes | Completed | 2024-12-04 | 2025-07-31 | ClinicalTrials.gov |
| NCT05346562 | Oral Cannabidiol Effect on Blood Pressure in Hypertensive Patients | Phase1 | Hypertension | Completed | 2022-04-08 | 2022-10-05 | ClinicalTrials.gov |
| NCT03295903 | Cannabinoid Supplementation on Vascular and Cognitive Function | Early_Phase1 | Diet Modification | Unknown | 2018-01-01 | 2021-10-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Cannabidiol supplement | Other | Phase EARLY_PHASE1 | Diet Modification | UNKNOWN | NCT03295903 |
| Placebo | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT05346562 |
| Cannabidiol | Other | Phase PHASE1 | Hypertension | COMPLETED | NCT05346562 |
| Arm 5- Tirzepatide | Other | Phase PHASE1 | Type2diabetes | COMPLETED | NCT06648031 |
| Arm 4 - Rybelsus medication (semaglutide) alone | Drug | Phase PHASE1 | Type2diabetes | COMPLETED | NCT06648031 |
| Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide | Other | Phase PHASE1 | Type2diabetes | COMPLETED | NCT06648031 |
| Arm 2 - DehydraTECH-semaglutide alone | Other | Phase PHASE1 | Type2diabetes | COMPLETED | NCT06648031 |
| Arm 1 - DehydraTECH-CBD alone | Other | Phase PHASE1 | Type2diabetes | COMPLETED | NCT06648031 |
| Arm 5- Tirzepatide | DRUG | Phase PHASE1 | Type2diabetes | COMPLETED | NCT06648031 |
| Arm 4 - Rybelsus medication (semaglutide) alone | DRUG | Phase PHASE1 | Type2diabetes | COMPLETED | NCT06648031 |
| Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide | DRUG | Phase PHASE1 | Type2diabetes | COMPLETED | NCT06648031 |
| Arm 2 - DehydraTECH-semaglutide alone | DRUG | Phase PHASE1 | Type2diabetes | COMPLETED | NCT06648031 |
| Arm 1 - DehydraTECH-CBD alone | DRUG | Phase PHASE1 | Type2diabetes | COMPLETED | NCT06648031 |